Mithramycin, an Agent for Developing New Therapeutic Drugs for Neurodegenerative Diseases
-
- Osada Nobuhiro
- Laboratory of Pharmacology, School of Pharmacy, Nihon University, Japan
-
- Kosuge Yasuhiro
- Laboratory of Pharmacology, School of Pharmacy, Nihon University, Japan
-
- Ishige Kumiko
- Laboratory of Pharmacology, School of Pharmacy, Nihon University, Japan
-
- Ito Yoshihisa
- Laboratory of Pharmacology, School of Pharmacy, Nihon University, Japan
Bibliographic Information
- Other Title
-
- Current Perspective : Mithramycin, an Agent for Developing New Therapeutic Drugs for Neurodegenerative Diseases
Search this article
Abstract
Mithramycin A (MTM) has been shown to inhibit cancer growth by blocking the binding of Sp-family transcription factors to gene regulatory elements and is used for the treatment of leukemia and testicular cancer in the United States. In contrast, MTM has also been shown to exert neuroprotective effects in normal cells. An earlier study showed that MTM protected primary cortical neurons against oxidative stress–induced cell death. Recently, we demonstrated that MTM suppressed endoplasmic reticulum (ER) stress–induced neuronal death in organotypic hippocampal slice cultures and cultured hippocampal cells through attenuation of ER stress–associated signal proteins. We also found that MTM decreased neuronal death in area CA1 of the hippocampus after transient global ischemia/reperfusion in mice and restored the ischemia/reperfusion-induced impairment of long-term potentiation in this area. MTM has been shown to prolong the survival of Huntington’s disease model mice and to attenuate dopaminergic neurotoxicity in mice after repeated administration of methamphetamine. In this review, we provide an up to date overview of neuroprotective effects of MTM and less toxic MTM analogs, MTM SK and MTM SDK, on some of the neurodegenerative diseases and discuss the promise of MTM as an agent for developing new therapeutic drugs for such diseases.
Journal
-
- Journal of Pharmacological Sciences
-
Journal of Pharmacological Sciences 122 (4), 251-256, 2013
The Japanese Pharmacological Society
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282680157391616
-
- NII Article ID
- 10031196198
-
- NII Book ID
- AA11806667
-
- COI
- 1:CAS:528:DC%2BC3sXhsVaiu7%2FO
-
- ISSN
- 13478648
- 13478613
-
- NDL BIB ID
- 024779184
-
- PubMed
- 23902990
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- Abstract License Flag
- Disallowed